← Back to Screener
Xenetic Biosciences, Inc. (XBIO)
Price$3.56
Favorite Metrics
Price vs S&P 500 (26W)-71.36%
Price vs S&P 500 (4W)2.51%
Market Capitalization$7.73M
All Metrics
Book Value / Share (Quarterly)$3.23
P/TBV (Annual)1.46x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)20.29%
Cash Flow / Share (Quarterly)$-1.00
Price vs S&P 500 (YTD)53.12%
Gross Margin (TTM)98.68%
Net Profit Margin (TTM)-90.07%
EPS (TTM)$-1.63
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$-1.63
Revenue Growth (5Y)46.57%
EPS (Annual)$-1.58
ROI (Annual)-36.25%
Gross Margin (Annual)97.89%
Net Profit Margin (5Y Avg)-256.27%
Cash / Share (Quarterly)$3.44
Revenue Growth QoQ (YoY)18.11%
ROA (Last FY)-32.05%
Revenue Growth TTM (YoY)19.04%
EBITD / Share (TTM)$-1.66
ROE (5Y Avg)-44.62%
Operating Margin (TTM)-95.23%
Cash Flow / Share (Annual)$-1.00
P/B Ratio1.05x
P/B Ratio (Quarterly)0.67x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)-0.05x
Net Interest Coverage (TTM)-4.23x
ROA (TTM)-43.63%
EPS Incl Extra (Annual)$-1.58
Current Ratio (Annual)8.32x
Quick Ratio (Quarterly)8.14x
3-Month Avg Trading Volume0.03M
52-Week Price Return-37.59%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$14.05
P/S Ratio (Annual)2.60x
Asset Turnover (Annual)0.36x
52-Week High$13.93
Operating Margin (5Y Avg)-265.97%
EPS Excl Extra (Annual)$-1.58
Tangible BV CAGR (5Y)75.69%
26-Week Price Return-67.37%
Quick Ratio (Annual)8.14x
13-Week Price Return47.21%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.32x
Enterprise Value$-0.15
Revenue / Share Growth (5Y)20.54%
Asset Turnover (TTM)0.48x
Book Value / Share Growth (5Y)-25.48%
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-90.07%
Cash / Share (Annual)$3.44
3-Month Return Std Dev88.33%
Net Income / Employee (TTM)$-1
ROE (Last FY)-36.25%
Net Interest Coverage (Annual)-22.81x
EPS Basic Excl Extra (Annual)$-1.58
P/FCF (TTM)1.52x
Receivables Turnover (TTM)5.06x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.63
Receivables Turnover (Annual)5.06x
ROI (TTM)-51.25%
P/S Ratio (TTM)2.60x
Pretax Margin (5Y Avg)-256.27%
Revenue / Share (Annual)$1.75
Tangible BV / Share (Annual)$14.05
Price vs S&P 500 (52W)-44.87%
Year-to-Date Return55.76%
5-Day Price Return7.30%
EPS Normalized (Annual)$-1.58
ROA (5Y Avg)-40.29%
Net Profit Margin (Annual)-90.07%
Month-to-Date Return26.12%
Cash Flow / Share (TTM)$-2.92
EBITD / Share (Annual)$-1.66
Operating Margin (Annual)-95.23%
ROI (5Y Avg)-44.62%
EPS Basic Excl Extra (TTM)$-1.63
P/TBV (Quarterly)1.46x
P/B Ratio (Annual)0.67x
Pretax Margin (TTM)-90.07%
Book Value / Share (Annual)$3.23
Price vs S&P 500 (13W)46.52%
Beta2.36x
P/FCF (Annual)5.23x
Revenue / Share (TTM)$1.37
ROE (TTM)-51.25%
52-Week Low$1.90
Analyst Recommendations
Nov 2025
Dec 2025
Jan 2026
Feb 2026
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
XBIOXenetic Biosciences, Inc. | 2.60x | 19.04% | 98.68% | — | $3.56 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Xenetic Biosciences Inc is a biopharmaceutical company developing DNase-based therapies for difficult-to-treat cancers. The company's proprietary DNase technology targets neutrophil extracellular traps (NETs) to enhance the effectiveness of existing cancer treatments and immunotherapies. Xenetic is advancing a systemic DNase program as an adjunctive therapy for pancreatic cancer and other metastatic solid tumors.